The Therapeutic Potential of Marijuana and PsychedelicsNovember 13th 2017
Most studies on the potential of marijuana, classic hallucinogens, 3,4-methylenedioxymethamphetamine, and ketamine have been small with methodological flaws, but the promising results from existing studies suggest that larger studies are warranted, said William M. Suavé, MD, medical director, Greenbrook TMS NeuroHealth Centers, during a presentation on the therapeutic potential of illicit drugs.
Combining Psychotherapy and Medication to Improve Outcomes in Patients With Axis I DisordersNovember 13th 2017
During a session at the 2017 Neuroscience Education Institute (NEI) Congress, Ira D. Glick, MD, professor emeritus, Department of Psychiatry and Behavioral Sciences, Stanford School of Medicine, emphasized the importance of combining psychological and psychopharmacologic strategies for patients with Axis I disorders and provided guidelines for administering the combination.
The Effects of Misdiagnosing Depression With Mixed Features as Unipolar DepressionNovember 12th 2017
Roger S. McIntyre, MD, FRCPC, professor, Departments of Psychiatry and Pharmacology, University of Toronto, and of the Head, Mood Disorders, Psychopharmacology Unit, University Health Network, discussed the contributing factors and effects of misdiagnosing or inappropriately treating patients with antidepressants.
Emotional Dysregulation and Executive Dysfunction in Patients With ADHD and Bipolar DisorderNovember 12th 2017
During a session on distinguishing between bipolar disorder and attention-deficit/hyperactivity disorder, David W. Goodman, MD, FAPA, assistant professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, and director and founder, Adult Attention Deficit Disorder Center of Maryland, explained that many of the symptoms for the 2 disorders overlap.
Pharmacogenomic Testing Tool Can Reduce Utilization of BenzodiazepineNovember 12th 2017
An economic analysis presented at the 2017 Neuroscience Educational Institute (NEI) Congress in Colorado Springs, Colorado, showed that pharmacogenomic testing in patients with specific psychiatric disorders can reduce the utilization of benzodiazepines.
The Effects of Chronic Fear on a Person's HealthNovember 11th 2017
At the 2017 Neuroscience Education Institute (NEI) Congress, a Friday session focused on the physiology of fear and its impact on wellness. It was presented by Mary D. Moller, PhD, DNP, ARNP, PMHCNS-BC, CPRP, FAAN, associate professor, Pacific Lutheran University School of Nursing, and director of Psychiatric Services, Northwest Center for Integrated Health.
How Exercise, Diet, Sleep, and Hearing Affect Brain AgingNovember 11th 2017
Exercise, diet, sleep, and hearing are 4 major factors that impact our aging, said Stephen M. Stahl, MD, PhD, adjunct professor of psychiatry, University of California San Diego during a session at the 2017 Neuroscience Educational Institute (NEI) Congress.
Knowing When to Switch or Augment Treatment in Patients With Major Depressive DisorderNovember 10th 2017
Only 1 in 3 patients will achieve remission on their first antidepressant, and 67% of patients require 4 antidepressant trials before symptoms remit, said Thomas L. Schwartz, MD, during a session on strategies for switching, combining, or augmenting treatments for patients with major depressive disorder.
The Role of Genes in Psychiatric Disorders and How Genetic Testing Can Be UsedNovember 10th 2017
There is no known gene for any major psychiatric disorder, nor is one ever likely to be found, explained Stephan M. Stahl, MD, PhD, adjunct professor of psychiatry, University of California San Diego, during an overview of the age of personalized medicine and the role of pharmacogenetics at a session of the 2017 Neuroscience Education Institute Congress.